Racura Oncology Presents Bisantrene MYC Data at Frontiers in Cancer Science 2026 Conference

Racura's preclinical data confirm (E,E)-bisantrene as the active MYC-silencing isomer.

What the company is saying

Racura Oncology Limited (ASX:RAC) is highlighting new preclinical evidence that (E,E)-bisantrene is the active isomer responsible for stabilizing the MYC G-quadruplex and suppressing MYC gene expression. The company frames these findings as foundational for its lead asset RC220, which is being clinically developed for multiple oncology indications. The announcement emphasizes the specificity and potency of (E,E)-bisantrene, especially compared to its isomer mixtures, and positions this as a scientific rationale for RC220’s proprietary formulation. CEO Daniel Tillett, Ph.D., is quoted to reinforce confidence in the MYC-directed mechanism and the strategic focus on (E,E)-bisantrene. Racura also points to ongoing research collaborations with Purdue University and clinical programs including the EMILI, HARNESS, and CPACS trials. The tone is assertive, aiming to connect robust preclinical results with the company’s broader clinical ambitions, but does not provide clinical or financial data.

What the data suggests

The disclosed data show that exposure of (E,E)-bisantrene to blue (440 nm) light reduces its content in solution to approximately 60% after 15 minutes and 40% after one hour, with near-complete loss after four hours. In MDA-MB-231 breast cancer cells, pure (E,E)-bisantrene suppressed MYC gene expression with a half-maximal effective concentration (EC50) of 277 nM, while light-exposed isomer mixtures required 514 nM to 1,166 nM for similar effect. For cancer cell viability, pure (E,E)-bisantrene achieved a half-maximal inhibitory concentration (IC50) of 266 nM, compared to 310 nM to 825 nM for the mixtures. An isomer mixture containing 62% (E,E)-bisantrene was significantly less effective at stabilizing the MYC G-quadruplex than the pure isomer, but this effect was reversed when the (E,E)-bisantrene content was matched. The data are detailed and quantitative, supporting the claim that (E,E)-bisantrene is the key active form for MYC silencing. No clinical trial progress, enrollment, or financial figures are disclosed, so the evidence is limited to preclinical efficacy.

Analysis

The announcement is upbeat, highlighting new preclinical data on (E,E)-bisantrene's mechanism of action and its potential as a cancer therapeutic. The measurable progress is limited to detailed preclinical results (concentration-response data, isomerization effects), which are robust and well-supported. However, the narrative extends these findings to support the ongoing clinical development of RC220 and its potential impact across multiple oncology indications, without providing any clinical trial data, enrollment numbers, or financial metrics. The majority of forward-looking statements concern future research, ongoing collaborations, and the advancement of RC220 in clinical trials, but no immediate or near-term benefits are disclosed. There is no mention of large capital outlays or imminent financial impact, so capital intensity is not flagged. The gap between narrative and evidence lies in the extrapolation from preclinical findings to clinical and commercial outcomes, which remain unproven and long-dated.

Risk flags

• ●The announcement is based entirely on preclinical data, which often do not translate directly into clinical efficacy or safety in humans. This gap between laboratory results and patient outcomes is a major risk for drug development.
• ●No clinical trial enrollment, interim results, or milestone achievements are disclosed, making it impossible to assess the pace or likelihood of clinical progress. This lack of operational detail increases uncertainty around timelines and value realization.
• ●There is no financial data, cash position, or funding update provided, so investors cannot gauge the company’s ability to sustain its clinical programs or manage capital requirements. This omission leaves open questions about financial runway and dilution risk.

Bottom line

Racura’s update provides robust preclinical evidence that (E,E)-bisantrene is the active isomer for MYC gene silencing, supporting the scientific rationale for RC220’s proprietary formulation. The quantitative data are compelling at the laboratory level, but there is no disclosure of clinical trial progress, patient outcomes, or financial position. Investors should recognize that the value proposition remains tied to successful clinical translation, which is inherently uncertain and likely long-dated. The absence of operational and financial metrics means the announcement does not change the risk profile or investment case in the near term. The most important takeaway is that while the science is advancing, material value realization will depend on forthcoming clinical and financial disclosures.

Announcement summary

(ASX:RAC) Racura Oncology Limited announced new preclinical data on the MYC-directed mechanism of action of (E,E)-bisantrene, presented as a poster at the Frontiers in Cancer Science (FCS) 2026 Conference in Singapore from 11–13 November 2026. The data demonstrate that (E,E)-bisantrene is the major active isomer of bisantrene capable of stabilizing the G-quadruplex in the MYC gene promoter region, resulting in reduced MYC gene expression and MYC protein levels. In preclinical studies, exposure of (E,E)-bisantrene to blue (440 nm) light reduced its content in solution to approximately 60% after 15 minutes, approximately 40% after one hour, and to an unquantifiable level after four hours. In MDA-MB-231 breast cancer cells, pure (E,E)-bisantrene suppressed MYC gene expression with a half-maximal effective concentration of 277 nM, compared with 514 nM to 1,166 nM for the light-exposed isomer mixtures. Pure (E,E)-bisantrene reduced cancer cell viability with a half-maximal inhibitory concentration of 266 nM, compared with 310 nM to 825 nM for the mixtures. An isomer mixture containing 62% (E,E)-bisantrene stabilized the MYC G-quadruplex significantly less than pure (E,E)-bisantrene at the same concentration, and stabilization was restored when the amount of (E,E)-bisantrene was matched. These findings build on MYC gene expression inhibition data for (E,E)-bisantrene presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting in April 2026. Racura continues to investigate this mechanism through its ongoing research collaboration with Purdue University. The poster, entitled "Light-Induced Isomerization Attenuates (E,E)-Bisantrene G-Quadruplex Binding and MYC Silencing," reports work by Racura scientists and collaborators at the University of Wollongong, Australia. Daniel Tillett, Ph.D., Chief Executive Officer of Racura Oncology, stated that these data confirm (E,E)-bisantrene as the active form stabilizing G-quadruplex structures and inhibiting MYC gene expression, supporting the development of RC220 as a proprietary formulation of (E,E)-bisantrene. RC220 is being clinically developed to target non-canonical G-quadruplex DNA and RNA structures enriched in oncogenic regulatory regions, including promoters, untranslated regions, and highly transcribed loci. (E,E)-bisantrene contains two hydrazone groups that can isomerize, and exposure to light converts it into (E,Z)- and potentially (Z,Z)-isomers. The FCS 2026 data indicate that the (E,E)-isomer is most responsible for MYC G-quadruplex stabilization, MYC suppression, and anticancer activity, supporting Racura's development of RC220 as a proprietary formulation of (E,E)-bisantrene. RC220 is designed to overcome drug solubility issues that prevent safe peripheral intravenous infusion. (E,E)-bisantrene is a clinically validated small molecule anticancer agent that primarily functions via G4-DNA and RNA binding, leading to potent transcriptional silencing of MYC and downstream pathways. G4-binding by (E,E)-bisantrene also inhibits topoisomerase II and telomerase, as well as modulates the m6A RNA pathway. Racura is advancing RC220 in multiple oncology indications, including the EMILI Phase 2b/3 trial in acute myeloid leukemia (AML), the HARNESS Phase 1 trial in combination with osimertinib in mutant EGFR non-small cell lung cancer (EGFRm NSCLC), and the CPACS Phase 1 trial in combination with doxorubicin for solid tumor patients.

Disagree with this article?